Correction: XenoPort-Glaxo Drug
NEW YORK (AP) In a Nov. 9 story and headline about a Food and Drug Administration review of a drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, The Associated Press reported erroneously on the nature of the FDA review. The FDA is considering an application for the drug in restless legs syndrome, not neuropathic pain.
- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,318.16 | 1,091.38 | 2,146.04 | 33.56 |
Oil *
77.53
|
|
DOWN
14.28
|
DOWN
3.52
|
DOWN
10.78
|
UP
0.07
|
10 Yr
3.36%
SPDR Gold
112.94
|
|
-0.14%
|
-0.32%
|
-0.50%
|
+0.21%
|
Data delayed 20 minutes |
